Biomarkers of Alzheimer’s Disease
Posted on February 24th, 2017
Early detection of Alzheimer’s Disease is paramount to beginning early treatment. Early treatment – prior to high levels of amyloid beta tangles and permanent brain damage has a much higher chance of success.
Type 1 Alzheimer’s – Inflammatory
Posted on February 21st, 2017
Alzheimer’s disease (AD) is not one disease but more of a gradual change in many inputs – a network effect – similar to the downward slide a regional economy might experience during a recession. Alzheimer’s involves progressive neurodegeneration in the presence of misfolded proteins, poorly-understood inflammatory changes. So, Alzheimer’s a uniquely personalized degenerative condition: genetically, clinically, and pathologically heterogeneous (Sudduth et al) [R]. One clear marker of of Alzheimer’s is high levels of inflammation comorbid with cognitive impairment (often referred to as “brain fog” in the young) advancing to intermittent amnesia leading to true dementia.
Lymphatic Fluid and Immunotherapy
Posted on February 15th, 2017
Lymph is the fluid that circulates throughout the lymphatic system. Lymph fluids transport key immune system actors called immunoglobulins and antimicrobial medium and short chain fatty acids (SCFAs) through out the body.
The Biomarkers of Aging – How to Manage Aging
Posted on January 20th, 2017
What is measurable is manageable: tracking and managing the biomarkers of aging means longer health span.
At MaxWell Biosciences, we are aware that the longevity of human aging has dramatically changed throughout the evolution of the species. In order to track these ongoing changes in the rate of aging we must establish pathological biomarkers. Biomarkers of aging are changes in the body that are objectively measurable and show significant differences throughout the chronological stages of human life.